Chinese Equity Markets Lower on the Back of Weak Data

Equity markets across China were the weakest of the session as they reacted to a slew of weak data, including GDP, industrial production and weaker investment.



China data points to softer growth in Q4

Growth was expected to soften anyway, but overall it was a disappointment relative to already-softened expectations. At 4.9% y/y, it is the first time that GDP has fallen below 5% since Q1 2020 as the global pandemic was truly underway. Expectations landed around 5.2%, down from 7.9%. Exports accounted for 19.5% of GDP and final consumption accounted for 64.8%. A spokesman from the stats bureau said that China is able to achieve full-year economic targets despite this setback.

Industrial production was also disappointing, coming in at 3.1% m/m compared to 3.9% expected and down from 5.3% in August. This dragged the annual rate down by 4.1 percentage points to 11.8%. Urban investments also fell for a 7th consecutive month to 7.3%. Retail sales bucked the trend and rose 4.4% in September up from 2.5% and beating estimates if around 3.3%.

Overall data today points towards softer growth for Q4. And this means traders will place extra emphasis on leading indicators such as the PMI’s which can provide a forward look at potential growth. And given manufacturing and services PMI’s dipped below 50 in August due to lockdowns, then we’d need to see them pick up from current levels to revive hopes of a positive Q4 GDP print. In September manufacturing was flat at 50 according to the Caixin read, although services expanded at 53.4 compared with 46.7 previously. The ‘official’ NBS read for manufacturing contracted at 49.6, so leading indicators are not yet pointing to a rebound for growth in Q4.


Equities feel the heat of soft data

The soft data set took the wind out of the sails for investors. Heading into the data sentiment was buoyant, thanks to a strong finish on Wall Street and better than expected earnings reports. China’s equity markets are the weakest performer across the region with the CSI300 falling -1.5% after the open. The Hang Seng China Enterprise index (HSCE) is down around -1% and the Hang Seng is off by -0.7%. However, the China A50 index is the session’s worst performer and trades around -1.9% lower on the day.


The daily trend is now within a countertrend move after its rally from 14,847 stopped just shy of the 200-day eMA. It has fallen back to the 15,600 – 15,715 support zone highlighted in today’s Asian Open report, with the 50-day eMA providing support at the day’s low. If prices can stabilise around current levels then it may be able to form a corrective low, and a break above 15,850 brings the cycle high back into focus. Whilst a break beneath 15,600 warns of a deeper retracement, and we would look for support to build around the broken trendline. The daily trend remains bullish above the 14,847 low.



The Hang Seng is also interacting with its 50-day eMA, although it is currently capping as resistance. It has seen a strong rally from the October low but prices are now in a sideways range between 24,800 – 25,440. If prices retrace to the lower boundary of the zone then it may tempt dip-buyers who are anticipating a break above 25,500 as part of trend extension. Yet if prices break below 24,800 it suggests the market is either in a count trend move, or momentum has realigned with its longer-term bearish trend and could retest October’s low.


How to trade with City Index

You can trade easily trade with City Index by using these four easy steps:

  1. Open an account, or log in if you’re already a customer 

    Open an account in the UK
    Open an account in Australia
    Open an account in Singapore

  2. Search for the company you want to trade in our award-winning platform 
  3. Choose your position and size, and your stop and limit levels 
  4. Place the trade



This report is intended for general circulation only. It should not be construed as a recommendation, or an offer (or solicitation of an offer) to buy or sell any financial products. The information provided does not take into account your specific investment objectives, financial situation or particular needs. Before you act on any recommendation that may be contained in this report, independent advice ought to be sought from a financial adviser regarding the suitability of the investment product, taking into account your specific investment objectives, financial situation or particular needs.

StoneX Financial Pte. Ltd., may distribute reports produced by its respective foreign entities or affiliates within the StoneX group of companies or third parties pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed to a person in Singapore who is not an accredited investor, expert investor or an institutional investor (as defined in the Securities Futures Act), StoneX Financial Pte. Ltd. accepts legal responsibility to such persons for the contents of the report only to the extent required by law. Singapore recipients should contact StoneX Financial Pte. Ltd. at 6826 9988 for matters arising from, or in connection with the report.

In the case of all other recipients of this report, to the extent permitted by applicable laws and regulations neither StoneX Financial Pte. Ltd. nor its associated companies will be responsible or liable for any loss or damage incurred arising out of, or in connection with, any use of the information contained in this report and all such liability is hereby expressly disclaimed. No representation or warranty is made, express or implied, that the content of this report is complete or accurate.

StoneX Financial Pte. Ltd. is not under any obligation to update this report.

Trading CFDs and FX on margin carries a high level of risk that may not be suitable for some investors. Consider your investment objectives, level of experience, financial resources, risk appetite and other relevant circumstances carefully. The possibility exists that you could lose some or all of your investments, including your initial deposits. If in doubt, please seek independent expert advice. Visit for the complete Risk Disclosure Statement.